These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 8923474)
1. Metabolism of (-)-deprenyl and PF-(-)-deprenyl in brain after central and peripheral administration. Lajtha A; Sershen H; Cooper T; Hashim A; Gaál J Neurochem Res; 1996 Oct; 21(10):1155-60. PubMed ID: 8923474 [TBL] [Abstract][Full Text] [Related]
2. Analysis of deprenyl metabolites in the rat brain using HPLC-ES-MS. Kalász H; Bartók T; Szöko E; Haberle D; Kiss JP; Hennings EC; Magyar K; Fürst S Curr Med Chem; 1999 Apr; 6(4):271-8. PubMed ID: 10101213 [TBL] [Abstract][Full Text] [Related]
3. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Knoll J; Miklya I Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. Magyar K; Szatmáry I; Szebeni G; Lengyel J J Neural Transm Suppl; 2007; (72):165-73. PubMed ID: 17982891 [TBL] [Abstract][Full Text] [Related]
5. Urinary excretion of deprenyl metabolites. Lengyel J; Magyar K; Hollósi I; Bartók T; Báthori M; Kalász H; Fürst S J Chromatogr A; 1997 Feb; 762(1-2):321-6. PubMed ID: 9098991 [TBL] [Abstract][Full Text] [Related]
6. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. Lamensdorf I; Youdim MB; Finberg JP J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937 [TBL] [Abstract][Full Text] [Related]
7. Gas-chromatographic study on the stereoselectivity of deprenyl metabolism. Tarjányi Z; Kalász H; Szebeni G; Hollósi I; Báthori M; Fürst S J Pharm Biomed Anal; 1998 Aug; 17(4-5):725-31. PubMed ID: 9682156 [TBL] [Abstract][Full Text] [Related]
8. l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine. Melega WP; Cho AK; Schmitz D; Kuczenski R; Segal DS J Pharmacol Exp Ther; 1999 Feb; 288(2):752-8. PubMed ID: 9918585 [TBL] [Abstract][Full Text] [Related]
9. Incorporation of selegiline metabolites into hair after oral selegiline intake. Kronstrand R; Andersson MC; Ahlner J; Larson G J Anal Toxicol; 2001 Oct; 25(7):594-601. PubMed ID: 11599606 [TBL] [Abstract][Full Text] [Related]
10. Chiral characterization of deprenyl-N-oxide and other deprenyl metabolites by capillary electrophoresis using a dual cyclodextrin system in rat urine. Tábi T; Magyar K; Szöko E Electrophoresis; 2003 Aug; 24(15):2665-73. PubMed ID: 12900880 [TBL] [Abstract][Full Text] [Related]
11. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Yoshida T; Yamada Y; Yamamoto T; Kuroiwa Y Xenobiotica; 1986 Feb; 16(2):129-36. PubMed ID: 3083608 [TBL] [Abstract][Full Text] [Related]
12. Metabolic transformation of deprenyl enantiomers in rats. Szökö E; Kalász H; Magyar K Neurobiology (Bp); 1999; 7(2):247-54. PubMed ID: 10591057 [TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450-dependent metabolism of l-deprenyl in monkey (Cercopithecus aethiops) and C57BL/6 mouse brain microsomal preparations. Dragoni S; Bellik L; Frosini M; Matteucci G; Sgaragli G; Valoti M J Neurochem; 2003 Sep; 86(5):1174-80. PubMed ID: 12911625 [TBL] [Abstract][Full Text] [Related]
14. Discriminative stimulus and reinforcing effects of p-fluoro-L-deprenyl in monkeys. Yasar S; Gaal J; Justinova Z; Bergman J Psychopharmacology (Berl); 2005 Oct; 182(1):95-103. PubMed ID: 15990999 [TBL] [Abstract][Full Text] [Related]
15. Hair analysis for drugs of abuse. IX. Comparison of deprenyl use and methamphetamine use by hair analysis. Kikura R; Nakahara Y Biol Pharm Bull; 1995 Feb; 18(2):267-72. PubMed ID: 7742796 [TBL] [Abstract][Full Text] [Related]
16. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl]. Yasar S; Justinova Z; Lee SH; Stefanski R; Goldberg SR; Tanda G J Pharmacol Exp Ther; 2006 Apr; 317(1):387-94. PubMed ID: 16352699 [TBL] [Abstract][Full Text] [Related]
17. Determination of enantiomeric metabolites of l-deprenyl, d-methamphetamine, and racemic methamphetamine in urine by capillary electrophoresis: comparison of deprenyl use and methamphetamine use. Kim EM; Chung HS; Lee KJ; Kim HJ J Anal Toxicol; 2000; 24(4):238-44. PubMed ID: 10872569 [TBL] [Abstract][Full Text] [Related]
18. Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research. Yasar S; Goldberg JP; Goldberg SR J Neural Transm Suppl; 1996; 48():61-73. PubMed ID: 8988462 [TBL] [Abstract][Full Text] [Related]
19. Behaviour of (-)-deprenyl and its analogues. Magyar K J Neural Transm Suppl; 1994; 41():167-75. PubMed ID: 7931223 [TBL] [Abstract][Full Text] [Related]
20. Assessment of the N-oxidation of deprenyl, methamphetamine, and amphetamine enantiomers by chiral capillary electrophoresis: an in vitro metabolism study. Szöko E; Tábi T; Borbás T; Dalmadi B; Tihanyi K; Magyar K Electrophoresis; 2004 Aug; 25(16):2866-75. PubMed ID: 15352021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]